Cancer Research at the Greenebaum Comprehensive Cancer Center

UMGCCC is a National Cancer Institute-designated comprehensive cancer center, a distinction that places it in the top tier of cancer centers throughout the country. Your participation in the Maryland Half Marathon and 5K benefits our groundbreaking cancer research. Some of our focuses include: 

Bone Marrow Transplantation

Dr. Xuefang Cao was recently recruited to UMGCCC from the Roswell Park Cancer Institute in Buffalo.  He studies bone marrow transplantation and is researching how transplanted bone marrow cells attack the patient’s tumor in a beneficial way and how they may also attack the recipient’s normal tissues in ways that are harmful. The goal is to modify how transplants are performed in the future to maximize beneficial effects and minimize harmful effects. 

Enhancing Immunotherapy for Myeloma and other Cancers

Dr. Eduardo Davila is the co-leader of the UMGCCC Tumor Immunology and Immunotherapy program. The long-term focus of his research has been to develop anticancer immune-based therapeutics and to understand the cellular and molecular signals that promote the generation of potent and long-lasting tumor-specific immune cell responses. Dr. Davila has developed technologies which permit immunotherapy to be adapted to almost any identified tumor target.


To learn more about the Greenebaum Comprehensive Cancer Center, visit www.umgccc.org.